Clinical Trials

Alliance for Clinical Trials in Oncology

IRB
Details
Info
23-025
A011801-The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
22-015
A221805-Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study